We believe the results presented here comprehensively address both questions in the setting of high-risk aggressive neuroblastoma, where (a) genetic rearrangements with array CGH, QPCR and immunoblotting identified the genes whose genetic alterations accumulate during neuroblastoma progression and (b) clinical outcomes (overall survival) association studies as well as clinical tumor grade-correlated RALYL expression identified genes whose expression may be responsible for the acquisition of aggressive disease. This evidence concerns the gene RALYL and neuroblastoma.